GRELL, Peter, Katarína PETRÁKOVÁ, Marta ŠIMÍČKOVÁ, Marek SVOBODA, Miloslava NEKULOVÁ, Ladislav PECEN, Rostislav VYZULA a Rudolf NENUTIL. Serum HER-2/neu: a tumor marker for monitoring response to treatment of metastatic breast cancer with trastuzumab. In 19th meeting of European Association For Cancer Research. 1. vyd. Budapešť: European Association for Cancer Research, 2006. s. 207-207, 1 s.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Serum HER-2/neu: a tumor marker for monitoring response to treatment of metastatic breast cancer with trastuzumab
Název česky Sérová HER-2/neu: nádorový marker pro monitoring odpovědi na léčbu trastuzumabem u metastatického karcinomu prsu
Autoři GRELL, Peter, Katarína PETRÁKOVÁ, Marta ŠIMÍČKOVÁ, Marek SVOBODA, Miloslava NEKULOVÁ, Ladislav PECEN, Rostislav VYZULA a Rudolf NENUTIL.
Vydání 1. vyd. Budapešť, 19th meeting of European Association For Cancer Research, od s. 207-207, 1 s. 2006.
Nakladatel European Association for Cancer Research
Další údaje
Originální jazyk angličtina
Typ výsledku Stať ve sborníku
Obor 30200 3.2 Clinical medicine
Stát vydavatele Velká Británie
Utajení není předmětem státního či obchodního tajemství
Organizační jednotka Lékařská fakulta
Klíčová slova anglicky serum her2/neu;trastuzumab;breast cancer
Štítky breast cancer, serum her2/neu, trastuzumab
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnil: prof. MUDr. Marek Svoboda, Ph.D., učo 19402. Změněno: 25. 1. 2008 18:19.
Anotace
Introduction: HER-2/neu, the oncoprotein from growth factor receptor family, is overexpressed in primary tumor tissue in approximately 30% patients with breast cancer. Extracellular domain of this oncoprotein is released into the circulation and by recent studies it has prognostic and predictive signification similar to HER-2/neu in tissue. Material and Methods: We evaluated dynamics of serum HER-2/neu (S_HER2) changes during the course of trastuzumab-based therapy, by the specific antibody directed against the extracellular domain (ELISA, Oncogene Science, USA). We had opportunity to repeatedly tested S_HER2 in 69 patients with metastatic breast cancer undergoing treatment in years 200-2005 in our institute. Results: Patients without the response to treatment at the time of the first restaging (3 months), had significantly elevated S_HER2 levels, that generally do not drop below the discriminatory level. The patients with the best clinical response achieved (complete or partial response) are commonly S_HER2 negative after 3 months of the therapy, even if they were serum-positive at the beginning of the treatment. Serum CA15-3 and CEA levels do not show significant differences in this two groups of responders. Likewise in longitudinally monitoring over the time course of trastuzumab-based treatment the predictor of the therapy failure is mainly elevated S_HER2. Conclusion: Monitoring the concentrations of serum HER2 during the trastuzumab therapy appears to be a suitable therapy efficacy validation parameter both at the start and during long-term therapy application. Acknowledgements: The work was supported by grants from IGA MZCR: No. NR/8335-3 and No. NR/8270-3.
Anotace česky
Introduction: HER-2/neu, the oncoprotein from growth factor receptor family, is overexpressed in primary tumor tissue in approximately 30% patients with breast cancer. Extracellular domain of this oncoprotein is released into the circulation and by recent studies it has prognostic and predictive signification similar to HER-2/neu in tissue. Material and Methods: We evaluated dynamics of serum HER-2/neu (S_HER2) changes during the course of trastuzumab-based therapy, by the specific antibody directed against the extracellular domain (ELISA, Oncogene Science, USA). We had opportunity to repeatedly tested S_HER2 in 69 patients with metastatic breast cancer undergoing treatment in years 200-2005 in our institute. Results: Patients without the response to treatment at the time of the first restaging (3 months), had significantly elevated S_HER2 levels, that generally do not drop below the discriminatory level. The patients with the best clinical response achieved (complete or partial response) are commonly S_HER2 negative after 3 months of the therapy, even if they were serum-positive at the beginning of the treatment. Serum CA15-3 and CEA levels do not show significant differences in this two groups of responders. Likewise in longitudinally monitoring over the time course of trastuzumab-based treatment the predictor of the therapy failure is mainly elevated S_HER2. Conclusion: Monitoring the concentrations of serum HER2 during the trastuzumab therapy appears to be a suitable therapy efficacy validation parameter both at the start and during long-term therapy application. Acknowledgements: The work was supported by grants from IGA MZCR: No. NR/8335-3 and No. NR/8270-3.
Návaznosti
NR8335, projekt VaVNázev: Predikce chemosenzitivity / chemorezistence na cílenou protinádorovou terapii u pacientek s karcinomem prsu s prokázanou HER-2 pozitivitou, na podkladě analýzy Akt signální dráhy a sérové hladiny HER-2 receptoru
VytisknoutZobrazeno: 21. 10. 2020 19:37